Boston Trust Walden Corp Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Boston Trust Walden Corp increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 204,483 shares of the medical research company's stock after acquiring an additional 8,338 shares during the period. Boston Trust Walden Corp owned about 0.40% of Charles River Laboratories International worth $37,748,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after buying an additional 3,738,018 shares during the last quarter. State Street Corp lifted its stake in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock worth $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock worth $101,483,000 after acquiring an additional 32,311 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $2.62 during midday trading on Friday, hitting $163.65. 564,421 shares of the company's stock were exchanged, compared to its average volume of 938,557. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The business's fifty day moving average price is $180.61 and its two-hundred day moving average price is $193.62. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.48, a PEG ratio of 6.25 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12-month low of $159.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 EPS. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on CRL shares. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. CLSA lowered Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 target price for the company. in a report on Monday, November 18th. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).